Market Closed -
Bombay S.E.
03:30:49 13/05/2024 pm IST
5-day change
1st Jan Change
472
INR
+2.14%
-5.85%
-3.49%
Aarti Drugs Limited's Equity Buyback announced on July 21, 2023, has closed with 665,000 shares, representing 0.72% for INR 598.5 million.
On August 17, 2023, the company concluded the Market Repurchase.
Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024
06/05
Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
03/05
CI
Aarti Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2024
03/05
CI
Aarti Drugs Limited Announces Executive Cessation
29/03
CI
Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility
31/01
MT
Aarti Drugs Limited Initiates Commercial Production of Dermatology Product At New Facility in Tarapur, Maharashtra
30/01
CI
Transcript : Aarti Drugs Limited, Q3 2024 Earnings Call, Jan 25, 2024
25/01
Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24
24/01
CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
24/01
CI
Transcript : Aarti Drugs Limited, Q2 2024 Earnings Call, Oct 20, 2023
20/23/20
Aarti Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
19/23/19
CI
Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on July 21, 2023.
28/23/28
CI
Aarti Drugs Limited's Equity Buyback announced on July 21, 2023, has closed with 665,000 shares, representing 0.72% for INR 598.5 million.
17/23/17
CI
Aarti Drugs Clocks Gains in Fiscal Q1 Consolidated Profit
24/23/24
MT
Transcript : Aarti Drugs Limited, Q1 2024 Earnings Call, Jul 24, 2023
24/23/24
Aarti Drugs Limited announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.
21/23/21
CI
Aarti Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
21/23/21
CI
Aarti Drugs Limited authorizes a Buyback Plan.
21/23/21
CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023.
14/23/14
CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023.
14/23/14
CI
Transcript : Aarti Drugs Limited, Q4 2023 Earnings Call, May 02, 2023
02/23/02
Aarti Drugs' Consolidated Profit Climbs in Fiscal Q4
01/23/01
MT
Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
29/23/29
CI
Transcript : Aarti Drugs Limited, Q3 2023 Earnings Call, Jan 30, 2023
30/23/30
Aarti Drugs' Consolidated Net Profit Declines in Fiscal Q3
30/23/30
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
More about the company
Average target price
542
INR
Spread / Average Target
+14.83%
Consensus
1st Jan change
Capi.
-3.49% 51Cr +29.48% 68TCr +30.34% 57TCr -3.93% 36TCr +17.63% 33TCr +4.17% 28TCr +16.21% 24TCr +9.66% 21TCr -6.83% 20TCr +6.95% 17TCr
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1